Acquired resistance L747S mutation in an epidermal growth factor receptor‑tyrosine kinase inhibitor‑naïve patient: A report of three cases

Yamaguchi,Fumihiro; Fukuchi,Kunihiko; Yamazaki,Yohei; Takayasu,Hiromi; Tazawa,Sakiko; Tateno,Hidetsugu; Kato,Eisuke; Wakabayashi,Aya; Fujimori,Mami; Iwasaki,Takuya; Hayashi,Makoto; Tsuchiya,Yutaka; Yamashita,Jun; Takeda,Norikazu; Kokubu,Fumio

doi:10.3892/ol.2013.1705

Acquired resistance L747S mutation in an epidermal growth factor receptor‑tyrosine kinase inhibitor‑naïve patient: A report of three cases

Authors:
- Fumihiro Yamaguchi
- Kunihiko Fukuchi
- Yohei Yamazaki
- Hiromi Takayasu
- Sakiko Tazawa
- Hidetsugu Tateno
- Eisuke Kato
- Aya Wakabayashi
- Mami Fujimori
- Takuya Iwasaki
- Makoto Hayashi
- Yutaka Tsuchiya
- Jun Yamashita
- Norikazu Takeda
- Fumio Kokubu
View Affiliations

Affiliations: Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Aoba‑ku, Yokohama 227‑8501, Japan, Department of Clinical Pathology, Showa University School of Medicine, Shinagawa‑ku, Tokyo 142‑8666, Japan
Published online on: November 25, 2013 https://doi.org/10.3892/ol.2013.1705
Pages: 357-360

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to report cases of epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI)‑naïve patients carrying a mutation associated with acquired resistance to the drug. Gene alterations in 77 lung carcinoma patients were analyzed by collecting and studying curette lavage fluid at the time of diagnosis. PCRs were performed to amplify mutation hotspot regions in EGFR genes. The PCR products were direct‑sequenced and the mutations confirmed by resequencing using different primers. Case 1 was a 78‑year‑old Japanese male diagnosed with stage IB lung adenocarcinoma who was found to have two EGFR mutations, G719S and L747S. Case 2 was a 73‑year‑old Japanese male diagnosed with stage IV squamous cell lung carcinoma and bone metastasis who had the EGFR mutation, L747S. Case 3 was an 82‑year‑old Japanese male diagnosed with hyponatremia due to inappropriate secretion of antidiuretic hormone and stage IIIB small cell lung carcinoma (SCLC) who had the EGFR mutation, L747S. Thus, the EGFR mutation L747S associated with acquired EGFR‑TKI resistance was detected in two non‑small cell lung carcinoma (NSCLC) patients and one SCLC patient, none of whom had ever received EGFR‑TKI. The patients were current smokers with stages at diagnosis ranging from IB to IV, and their initial tumors contained resistant clones carrying L747S. L747S may be associated with primary resistance. To the best of our knowledge, this study is the first report of an EGFR mutation associated with resistance to EGFR‑TKI in SCLC patients. The early detection of EGFR‑TKI resistance mutations may be beneficial in making treatment decisions for lung carcinoma patients, including those with SCLC.

View Figures

View References

1	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
2	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
3	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
4	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar
5	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824. 2007. View Article : Google Scholar
7	Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, et al: Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 126:651–655. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lin L and Bivona TG: Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract. 2012:8172972012.
9	Suda K, Mizuuchi H, Maehara Y and Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev. 31:807–814. 2012. View Article : Google Scholar
10	Yamaguchi F, Kugawa S, Tateno H, Kokubu F and Fukuchi K: Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer. 78:201–206. 2012. View Article : Google Scholar : PubMed/NCBI
11	Pallis AG, Voutsina A, Kalikaki A, Souqlakos J, Briasoulis E, et al: ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 97:1560–1566. 2007.
12	Jia XL and Chen G: EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer. 74:396–400. 2011. View Article : Google Scholar : PubMed/NCBI
13	Costa DB, Schumer ST, Tenen DG and Kobayashi S: Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 26:1182–1184. 2008. View Article : Google Scholar
14	Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, et al: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 14:7060–7067. 2008. View Article : Google Scholar : PubMed/NCBI
15	Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 23:2914–2919. 2012. View Article : Google Scholar
16	Fukui T, Tsuta K, Furuta K, Watanabe S, Asamura H, et al: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 98:1714–1719. 2007. View Article : Google Scholar : PubMed/NCBI
17	Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, et al: Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer. 58:411–413. 2007. View Article : Google Scholar : PubMed/NCBI
18	Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, et al: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 14:6092–6096. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zakowski MF, Ladanyi M and Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
20	Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K and Fukuoka M: EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol. 17:1028–1029. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lu HY, Mao WM, Cheng QY, Chen B, Cai JF, et al: Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett. 3:1288–1292. 2012.
22	Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra262011. View Article : Google Scholar : PubMed/NCBI
23	Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, et al: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin lung Cancer. 11:E1–E4. 2010. View Article : Google Scholar : PubMed/NCBI